Build status - In Progress
Search filters

Filters
Clear All

Phase

  • 33
  • 92
  • 1
  • 77
  • 37
  • 1
  • 109
  • 372
  • 173
  • 13
  • 16
  • 343
  • 368
  • 4

Found 372 oncology trials

A listing of oncology medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

99 years or below
All genders
Phase II and III: To compare time to DFS event (recurrence, second primary colorectal can cer or death) in ctDNA (+ve) cohort following resection of colon cancer treated with 5-FU (orcapecitabine) and oxaliplatin x 6 months or 5-FU, oxaliplatin and irinotecan x 6 months.
99 years or below
All genders
Phase II and III: To compare time to DFS event (recurrence, second primary colorectal can cer or death) in ctDNA (+ve) cohort following resection of colon cancer treated with 5-FU (orcapecitabine) and oxaliplatin x 6 months or 5-FU, oxaliplatin and irinotecan x 6 months.
99 years or below
All genders
Phase II and III: To compare time to DFS event (recurrence, second primary colorectal can cer or death) in ctDNA (+ve) cohort following resection of colon cancer treated with 5-FU (orcapecitabine) and oxaliplatin x 6 months or 5-FU, oxaliplatin and irinotecan x 6 months.
99 years or below
All genders
Phase II and III: To compare time to DFS event (recurrence, second primary colorectal can cer or death) in ctDNA (+ve) cohort following resection of colon cancer treated with 5-FU (orcapecitabine) and oxaliplatin x 6 months or 5-FU, oxaliplatin and irinotecan x 6 months.
 Preliminary Evaluation of Septin9 in Familial Adenomatous Polyposis Patients
1 years - 99 years
All genders
The purpose of this research study is to collect blood samples and applicable medical history from subjects diagnosed with hereditary colon cancer syndromes like FAP, Lynch Syndrome and MYK-associated polyposis and their family members. These samples will be used to evaluate the ability of a blood test to provide early …
 Long-Term Follow-up of Older HIV-infected Adults in the ACTG: Addressing Issues of Aging  HIV Infection and Inflammation
40 years - 99 years
All genders
Interventional
This study will look at the relationships between HIV infection, age and the immune system, and how these relate to the development of non-infectious illnesses such as heart disease, kidney disease, cancer, memory problems, and diabetes. Further, we will look at how demographic factors, behaviors, and social factors like social …
 Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
18 years - 39 years
All genders
Phase 3
Interventional
The first purpose of this study is to test the safety of the addition of a drug called inotuzumab to the usual chemotherapy drugs used for adolescent young adults (ages 18-39). Inotuzumab is investigational and is not FDA-approved. Additionally,this study is to compare any good and bad effects of using …
18 years - 99 years
All genders
Phase 2
Interventional
The main purpose of this research study is to determine the likelihood of cancer growing back in the throat or in the neck, 2 years after completion of radiation, if lower doses of radiation are used to a smaller area of the head and neck region, than is currently the …
 A DOUBLE BLIND  RANDOMIZED VEHICLE CONTROLLED  CROSSOVER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TOPICAL NALOXONE HYDROCHLORIDE LOTION  0.5%  FOR THE RELIEF OF PRURITUS IN PATIENTS WITH THE MYCOSIS FUNGOIDES (MF) FORM OF CUTANEOUS T-CELL LYMPHOMA (CTCL
99 years or below
All genders
Phase 3
This application is a request to execute a reliance agreement with Chesapeake an external IRB This study is being done to assess the efficacy and safety of Naloxone HCL Lotion 0.5% compared to Vehicle Lotion for the treatment of itching in patients with mycosis fungoides (MF), which is a type …
99 years or below
All genders
Phase 1
The purposes of this study are to see if the study drugs, venetoclax and gilteritinib can be safely and effectively combined for the treatment of patients with acute myeloid leukemia (AML) that has returned after prior treatment, or has failed to respond to prior treatment and identify potential biomarkers.
331 - 340 of 372